Indeed, Aslan et al (2020) previously tested the efficacy of colony‐stimulating factor 1 receptor (CSF1R) blockade using a neutralizing antibody to target TAMs and demonstrated improved treatment responses to ICB in a glioma model. This evidence concerns the gene CSF1R and central nervous system cancer.